Assessment of the Change of a Continuous Variable as a Function of its Initial Value

Christian Funck-Brentano

To cite this version:

Christian Funck-Brentano. Assessment of the Change of a Continuous Variable as a Function of its Initial Value. JAMA Cardiology, 2020, 10.1001/jamacardio.2020.6184. hal-03359393

HAL Id: hal-03359393
https://hal.sorbonne-universite.fr/hal-03359393
Submitted on 30 Sep 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Assessment of the Change of a Continuous Variable as a Function of its Initial Value


Christian Funck-Brentano MD, PhD\textsuperscript{1,2}

\textsuperscript{1} AP-HP Sorbonne Université, Pitié-Salpêtrière University Hospital, Department of Pharmacology and Clinical Investigation Centre, F-75013 Paris, France

\textsuperscript{2} INSERM, CIC-1901 and UMR-S 1166, Sorbonne University, Faculty of Medicine, F-75013 Paris, France

**Correspondence to:** Professor Christian Funck-Brentano

Clinical Investigation Center, Pitié-Salpêtrière Hospital, 47–83 Boulevard de l'Hôpital, 75013 Paris, France

Email: christian.funck-brentano@aphp.fr

Tel: +33 1 42 16 17 06

**Word count:** 209 (and 3 references)

**Competing interests:** The author has no competing interests to declare.
Funding: No sources of funding were used to assist in the preparation of this manuscript.
Marcusa et al\textsuperscript{1} have examined the influence of baseline Low-Density Lipoprotein Cholesterol (LDL-C) levels on percentage LDL-C reduction with statins, ezetimibe, and PCSK9 Inhibition. Using this mode of calculation, they report a higher percentage reduction in LDL-C with evolocumab in patients with lower baseline LDL-C levels, compared with a less marked percentage LDL-C reduction with simvastatin at lower baseline LDL-C levels, and no significant reduction of LDL-C levels with ezetimibe at lower baseline values. However, the use of percentage changes might be misleading since it is influenced by absolute baseline values, e.g. a 30\% reduction from 100 mg/dL converts to 70 mg/dL, a 30 mg/dL absolute reduction, whereas a 30\% reduction from 70 mg/dL converts to 49 mg/dL, a 21 mg/dL absolute reduction. More importantly, assessing the change of a parameter as a function of its baseline value is subject to bias because baseline values are used to calculate percentage changes.\textsuperscript{2,3} An analysis of the slope and intercept of the regression lines between LDL-C levels under treatment and baseline LDL-C levels using both linear and log scales, as promoted by MacGregor et al\textsuperscript{2}, seems more appropriate and might yield different results. This mode of analysis and of graphical display would allow a better comparison of evolocumab, simvastatin and ezetimibe.

References

